title: LOX-1: a new target for therapy for cardiovascular diseases.
abstract: There is much interest in the role of oxidant stress in an ever-increasing list of disease states. However, the precise mediator of oxidant stress and the stressor molecule/s have not been identified. Accordingly, trials of inhibitors of oxidant stress in animal models of disease states have met only limited success. The trials of traditional anti-oxidant vitamins have been largely unsuccessful in the treatment of a wide array of disease states in humans. Recent identification of LOX-1 in vascular endothelial cells and its activation by oxidant species have led to a marked improvement in our understanding of the pathology of several cardiovascular disease states. Here, we review the disease states where therapy targeted at LOX-1 inhibition might be helpful.
authors.affiliation: Division of Cardiology, University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System, Little Rock, AR 72205, USA. MehtaJL@UAMS.edu
authors.forename: Jawahar L
authors.initials: JL
authors.lastname: Mehta
authors.forename: Magomed
authors.initials: M
authors.lastname: Khaidakov
authors.forename: Paul L
authors.initials: PL
authors.lastname: Hermonat
authors.forename: Sona
authors.initials: S
authors.lastname: Mitra
authors.forename: Xianwei
authors.initials: X
authors.lastname: Wang
authors.forename: Guiseppe
authors.initials: G
authors.lastname: Novelli
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Sawamura
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D018384:Oxidative Stress / Q000187:drug effects; D051127:Scavenger Receptors, Class E / Q000037:antagonists & inhibitors* / Q000378:metabolism*
chemical_list: D051127:Scavenger Receptors, Class E